There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Neuropilin-1


Brief Information

Target Synonym:NRP1,CD304,VEGF165R,Neuropilin 1,Vascular Endothelial Cell Growth Factor 165 Receptor,NRP,Transmembrane Receptor,CD304 Antigen,BDCA4,NP1,Neuropilin-1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data


Loaded Human NRP1, Fc Tag (Cat. No. NR1-H5252) on Protein A Biosensor, can bind Human VEGF165, His Tag (Cat. No. VE5-H5248) with an affinity constant of 24.2 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) on SA Biosensor, can bind Human Neuropilin-1, His Tag (Cat. No. NR1-H5228) with an affinity constant of 21.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name



Neuropilin-1 (NRP1) is also known as Vascular endothelial cell growth factor 165 receptor (VEGF165R), CD antigen CD304, which belongs to the neuropilin family. The membrane-bound isoform 1 is a receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system. It mediates the chemorepulsant activity of semaphorins. It binds to semaphorin 3A, The PLGF-2 isoform of PGF, The VEGF-165 isoform of VEGF and VEGF-B. Coexpression with KDR results in increased VEGF-165 binding to KDR as well as increased chemotaxis. It may regulate VEGF-induced angiogenesis. The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CEND-1 CEND-1; iRGD; CIND-1 Phase 2 Clinical Drugcendr Triple Negative Breast Neoplasms; Carcinoma, Pancreatic Ductal Details

This web search service is supported by Google Inc.